Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.
This study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. The study is a chart review study.
Ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution.
This study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. Subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1-year, 2-years, 3-years, 4-years, 5-years).
GUARDIAN provides critical and contemporary data on patient outcomes, with additional insight into risk factors and patient-related indices. Both donor and recipient information along with procedural details (including transportation) will be collected to provide information for major discrete endpoints such as death, primary graft dysfunction, right ventricular dysfunction, CPB weaning, Inotrope use, CAV diagnosis, rejection, and survival.
Information about re-hospitalizations and re-transplantations is vital to address the integrated endpoint of days alive out of hospital, which is particularly relevant for this patient population. In addition, the number of in-hospital days and ICU time is closely tracked as the major resource utilized, after the initial transplant.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SherpaPak CTS Patients | Patients whose donor heart was transported with the SherpaPak CTS |
| |
| Standard Transport Patients | Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SherpaPak Cardiac Transport System | Device | The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients with Primary Graft Dysfunction | Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour) | one year |
| Number of Patients with Right Ventricular Dysfunction | hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD | one year |
| Length of ICU Stay | Length of time patient admitted to the intensive care unit post transplant | one year |
| Length of Hospital Stay | Length of time before patient is discharged from the hospital post transplant | one year |
| Survival | The length of patient survival up to 5 years will be compared | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalizations | Number of related hospitalizations post transplant | one year |
| CAV development | Number of patients who developed CAV between 1 and 5 years post transplant will be compared |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients registered on the heart transplant registry who receive a heart transplant at a participating center and do not meet any of the exclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andreas Zuckermann, MD | ALLGEMEINES KRANKENHAUS WIEN | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | United States | ||
| Medstar Washington Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42127213 | Derived | DeFilippis EM, Rodrigo ME, Loyaga-Rendon R, Shudo Y, Uriel N, Takeda K, D'Alessandro DA, Fiedler A. Preservation Strategy and Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis. ASAIO J. 2026 May 13. doi: 10.1097/MAT.0000000000002736. Online ahead of print. | |
| 38602105 | Derived |
Not provided
Not provided
Data will only be released as a summary of the results found at each center and overall. No individual patient data will be released.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| five years |
| Retransplant | The number of patients who were retransplanted will be compared | five years |
| Washington D.C. |
| District of Columbia |
| 20010 |
| United States |
| University of Florida Health Shands Hospital | Gainesville | Florida | 32608 | United States |
| Mayo Clinic | Jacksonville | Florida | 32224 | United States |
| AdventHealth Orlando | Orlando | Florida | 32803 | United States |
| Lutheran Hospital | Fort Wayne | Indiana | 46804 | United States |
| Kansas University Medical Center | Lawrence | Kansas | 66045 | United States |
| Tufts University Medical Center | Boston | Massachusetts | 02111 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Spectrum Health | Grand Rapids | Michigan | 49503 | United States |
| NewYork-Presbyterian Columbia University Irving Medical Center | New York | New York | 10032 | United States |
| Duke University | Durham | North Carolina | 27708 | United States |
| Cincinnati Children's Hospital | Cincinnati | Ohio | 45229 | United States |
| Pennslyvania State University | State College | Pennsylvania | 16801 | United States |
| Le Bonheur Children's Hospital | Memphis | Tennessee | 38103 | United States |
| Baylor University Medical Center | Dallas | Texas | 75246 | United States |
| Sentara Healthcare | Norfolk | Virginia | 23507 | United States |
| University of Graz | Graz | 8036 | Austria |
| Allgemeines Krankenhaus Wien | Vienna | 1090 | Austria |
| Hospital Universitario 12 de Octubre | Madrid | Spain |
| Hospital ClĂnico Universitario de Valladolid | Valladolid | Spain |
| Manchester University | Manchester | United Kingdom |
| Lerman JB, Patel CB, Casalinova S, Nicoara A, Holley CL, Leacche M, Silvestry S, Zuckermann A, D'Alessandro DA, Milano CA, Schroder JN, DeVore AD. Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System. Circ Heart Fail. 2024 May;17(5):e010904. doi: 10.1161/CIRCHEARTFAILURE.123.010904. Epub 2024 Apr 11. |
| 38503386 | Derived | D'Alessandro D, Schroder J, Meyer DM, Vidic A, Shudo Y, Silvestry S, Leacche M, Sciortino CM, Rodrigo ME, Pham SM, Copeland H, Jacobs JP, Kawabori M, Takeda K, Zuckermann A. Impact of controlled hypothermic preservation on outcomes following heart transplantation. J Heart Lung Transplant. 2024 Jul;43(7):1153-1161. doi: 10.1016/j.healun.2024.03.010. Epub 2024 Mar 19. |
| 38163452 | Derived | Moayedifar R, Shudo Y, Kawabori M, Silvestry S, Schroder J, Meyer DM, Jacobs JP, D'Alessandro D, Zuckermann A. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry. J Heart Lung Transplant. 2024 Apr;43(4):673-680. doi: 10.1016/j.healun.2023.12.013. Epub 2023 Dec 30. |
| 37678260 | Derived | Shudo Y, Leacche M, Copeland H, Silvestry S, Pham SM, Molina E, Schroder JN, Sciortino CM, Jacobs JP, Kawabori M, Meyer DM, Zuckermann A, D'Alessandro DA. A Paradigm Shift in Heart Preservation: Improved Post-transplant Outcomes in Recipients of Donor Hearts Preserved With the SherpaPak System. ASAIO J. 2023 Nov 1;69(11):993-1000. doi: 10.1097/MAT.0000000000002036. Epub 2023 Apr 5. |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D006333 | Heart Failure |
| D006330 | Heart Defects, Congenital |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided